Regeneron is acquiring Checkmate Pharmaceuticals and entered a clinical trial collaboration with SpringWorks Therapeutics to evaluate REGN5458 in multiple myeloma in combination with nirogacestat.
Janssen Victorious in Arbitration Battle Vs. Genmab over Darzalex Royalties
Expirations, FDA, Janssen, Johnson & Johnson, Multiple Myeloma, Patent, Patent Challenges, Patent Claims, Patent Disputes, Patent Exclusivity, Patent Expirations, Patent Infringement, Patent Lawsuits, Patent Licensing, Patent Litigation, Patent Protection, Patents, Therapeutics, U.S. Patent OfficeApr 08, 2022 By Jazmine Colatriano, M.S. BioSpace Johnson & Johnson’s Janssen Pharmaceutical secured an arbitrary win regarding royalty decisions stemming from the licensing and marketing of daratumumab, an anti-CD38 monoclonal antibody treatment that has multiple indications approved by the U.S. Food and Drug Administration (FDA). The confidential arbitration was conducted by a tribunal of three earlier this […]
Johnson & Johnson’s blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed.
bluebird bio announced that it expected to file three applications for regulatory approval by the end of 2019.
A look at five biotech companies in the cancer market and their upcoming releases at the 2017 American Society of Clinical Oncology (ASCO).
Danish biotech Genmab, which has seen its shares rocket 163 percent this year, is set for further gains as new research data showed increased potential for its Darzalex blood cancer treatment, analysts said on Wednesday. Patients using the drug had an overall survival rate of 90 percent and a 72 percent progression free survival rate […]
DARZALEX (daratumumab) Approved by U.S. FDA: First Human Anti-CD38 Monoclonal Antibody Available for the Treatment of Multiple Myeloma
Accelerated Drug Approvals, Approvals, Biotech, Biotechnology, Blood Cancers, Breakthrough Designation, Breakthrough Therapy, Breakthrough Therapy Designation, Breakthrough Therapy Designation, Clinical Trials, FDA/Regulatory, First-In-Class, Health, Human Anti-CD38 Monoclonal Antibody, Immunomodulatory Agents, Immunotherapy, Launches, Monoclonal Antibodies, Monoclonal Antibodies, Multiple Myeloma, Multiple Myeloma, Multiple Myeloma, New Drug Approvals, Priority Review, Priority Review, Product Launches, Proteasome Inhibitors, R&DFirst-in-class immunotherapy approved for multiple myeloma patients who have received three or more prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agent PR Newswire, HORSHAM, PA, November 16, 2015 Janssen Biotech, Inc., a Janssen Pharmaceutical Company of […]
U.S. regulators have approved an experimental treatment from Johnson & Johnson that may offer hope to multiple myeloma patients who have run out of other options against the blood cancer. The U.S. Food and Drug Administration on Monday said it had approved Darzalex (daratumumab) for patients who had already undergone at least three prior standard […]
Novartis AG said on Friday it received European Union approval for Farydak, a treatment for multiple myeloma that the company said gives new options for adult patients whose disease has progressed following standard therapy. Novartis received similar approval for Farydak from the U.S. Food and Drug Administration in February for treating multiple myeloma, a form […]